Citi on Cadila Healthcare | Cadila’s growth is likely to remain subdued over the full year, Citi says. The brokerage maintained a ‘Sell’ on concerns over high product concentration in the US.

Nomura on Cadila Healthcare | Cadila’s Q1 EBITDA was ahead of Nomura’s estimate on lower costs but the brokerage has concerns about the near-term outlook.

Citi on Hindustan Zinc | Citi has maintained a ‘Buy’ rating on the stock and raised the target price to Rs 240 from Rs 205 earlier.

Jefferies on Godrej Properties | The company remains Jefferies’ top pick. It has maintained a ‘Buy’ call and raised the target price to Rs 1,040 from Rs 1,020 earlier.